Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?

Thus far, none of the preclinically successful and promising immunomodulatory agents for type 1 diabetes mellitus (T1DM) has conferred stable, long-term insulin independence to diabetic patients. The majority of these immunomodulators are humanised antibodies that target immune cells or cytokines. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Brett, Trucco, Massimo, Giannoukakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139873/
https://www.ncbi.nlm.nih.gov/pubmed/21785616
http://dx.doi.org/10.1155/2011/432016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139873/
https://www.ncbi.nlm.nih.gov/pubmed/21785616
http://dx.doi.org/10.1155/2011/432016

Ejemplares similares